Even Less Incentive For Pharma To Innovate Threatens Global Health & Our Economy

With vaccination in the United States hitting the fourth wave of the COVID-19 epidemic, manufacturers of should have their day in the sun. Instead, they were once again at Washington cross hairs, the Buren executives as they had recently announced that they would support the deprivation of intellectual property protection with the COVID-19 vaccine. What it will do, however, is an indication to manufacturers that their much a needed investment in developing and producing lifesaving drugs may not be needed from a business perspective. Why spend your money on research and development of vaccines to eradicate Covid-19, malaria or other life a threatening diseases where you can just wait for someone else to do it and copy your work. Vaccines based on new technologies are nearing the end of a thousands years old disease that has plagued mankind, such as cancer and malaria, affecting rich and poor countries. (If there is no indication that life is a treasure this year, then we will never get the message!)

For example, malaria poses a threat to half of the world’s population, and in 2019 it killed 400,000 people. An effective vaccine will recreate history in a part of the world that has been recovering from colonial times and external oppression. Without lives saved, the economic consequences are shocking. In another study evaluating the effectiveness of childhood immunizations against infants in 41 countries with blacksmith Kline’s RTS vaccine (39% effective), it was found that the cost of health care programs was USD19.8 million and USD18 .4 million, with public spending amounting to USD65.6 million and USD61.0 million for the immunization program for children and infants respectively. ”And that is a cost savings with a much less effective vaccine than the new vaccine, a 77% effective R21 vaccine made by scientists at Oxford University.

The structure of the modern ecosystem of health care has already created a waste of resources facing companies A lot of time and effort goes into the development of very small ends of drugs that cost back hundreds of thousands of dollars. It is probably not enough to innovate to advance health care further, and now without the protection of the new patent products, manufacturers have little incentive to innovate.

Imagine what would happen if modern manufacturers did not have the means or motivation to invest in the science needed to create Covid-19 drugs. There is no doubt in my mind that we have not yet discussed the possibility that at least 70% of Americans may have been vaccinated on July 4.

Circumstances leading to support for copyright protection were long overdue. Calls for major visual displays in pharma have been happening for years. 2019 was especially full of people who criticized pharma for the cost of prescription drugs, which sparked a heated debate over whether there should be discounts for benefit managers to pass on to consumers. (Eventually, Trump’s administration rejected the corresponding law.) In the midst of these blatant publicity issues and the cost of prescription drugs to get airtime and during President Buren’s recent speech to Congress, calls for reform have already returned. But the most important change that needs to take place now is to look at the past year and see the value of science, the important role played by the historical public health industry, and the need for more – not less – motivation.

We must learn from this moment, not to go back to the old criticism and make it very difficult for people who get us out of this situation to do it again.

Get the best Forbes in your inbox with the latest information from experts all over the world.

Leave a Comment